441 related articles for article (PubMed ID: 27213490)
1. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
Camilleri B; Bridson JM; Halawa A
Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
3. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
[TBL] [Abstract][Full Text] [Related]
4. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
[TBL] [Abstract][Full Text] [Related]
5. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
6. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
[TBL] [Abstract][Full Text] [Related]
7. Limitations of current liver transplant immunosuppressive regimens: renal considerations.
Zhang W; Fung J
Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):27-32. PubMed ID: 28119255
[TBL] [Abstract][Full Text] [Related]
8. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
Whalen HR; Glen JA; Harkins V; Stevens KK; Jardine AG; Geddes CC; Clancy MJ
Transplantation; 2017 Feb; 101(2):430-436. PubMed ID: 26950724
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity.
Bentata Y
Artif Organs; 2020 Feb; 44(2):140-152. PubMed ID: 31386765
[TBL] [Abstract][Full Text] [Related]
10. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
11. Immunological risks of minimization strategies.
Snanoudj R; Tinel C; Legendre C
Transpl Int; 2015 Aug; 28(8):901-10. PubMed ID: 25809144
[TBL] [Abstract][Full Text] [Related]
12. Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences.
Shrestha BM
Exp Clin Transplant; 2017 Feb; 15(1):1-9. PubMed ID: 27938316
[TBL] [Abstract][Full Text] [Related]
13. The safety of calcineurin inhibitors for kidney-transplant patients.
Malvezzi P; Rostaing L
Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
15. Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients.
Baczkowska T; Durlik M
Pol Arch Med Wewn; 2009 May; 119(5):318-25. PubMed ID: 19579814
[TBL] [Abstract][Full Text] [Related]
16. Optimizing Immunosuppressive Regimens Among Living-Donor Renal Transplant Recipients.
Bakr MA; Nagib AM; Gheith OA; Hamdy AF; Refaie AF; Donia AF; Neamatalla AH; Eldahshan KF; Denewar AA; Abbas MH; Mostafa AI; Ghoneim MA
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):16-23. PubMed ID: 28260425
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
20. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
